London SPAC Axes 2 Deals For Biotech Firms Totaling £174M
Blank-check company Ashington Innovation PLC said Wednesday that it has terminated a £135 million ($172 million) agreement to acquire biotechnology firm Cell Therapy Ltd., which trades as Celixir, due to uncertainty...To view the full article, register now.
Already a subscriber? Click here to view full article